株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症 - パイプライン製品の分析

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321923
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.79円で換算しております。
Back to Top
市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症 - パイプライン製品の分析 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016
出版日: 2016年12月07日 ページ情報: 英文 45 Pages
概要

過去1年の間に入院や医療的な処置(透析、手術、カテーテルなど)を受けていないにもかかわらず、MRSAに感染した場合は市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症とされます。素因は血液透析、免疫システムの衰え、入院、外傷などです。皮膚の腫れ、疲労感、胸痛、熱、浮腫などが症状として挙げられます。

当レポートでは、市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Achaogen Inc.
  • Furiex Pharmaceuticals, Inc.
  • Galapagos NV
  • Novan, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • acorafloxacin
  • GLPG-1492
  • NVN-4428
  • SB-204
  • Small Molecules to Inhibit Beta Lactamase for Bacterial Infections
  • Synthetic Peptide for Multi-Drug Resistant Bacterial Infections

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8792IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Predisposing factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA may be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively.Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections.

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Overview
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics under Development by Companies
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Products under Development by Companies
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Galapagos NV
    • Merck & Co Inc
    • Syntiron LLC
    • Valevia UK Ltd
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acorafloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLPG-1492 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Staphylococcus aureus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAL-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Allergan Plc, H2 2016
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Galapagos NV, H2 2016
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Merck & Co Inc, H2 2016
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Syntiron LLC, H2 2016
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top